-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Purpose: Podocyte loss or damage is one of the earliest features observed in the pathogenesis of diabetic nephropathy (DKD), which is the main cause of end-stage renal failure in the world
Podocyte loss or damage is one of the earliest features observed in the pathogenesis of diabetic nephropathy (DKD), which is the main cause of end-stage renal failure worldwide
Results: Data from the PIMA DKD cohort and Nephroseq database showed that in the early stages of human type 2 DKD, glomerular IGFBP-1 was significantly reduced
Table glomerular IGFBP-1 decreases in the early stage of type 2 DKD
Table glomerular IGFBP-1 decreases in the early stage of type 2 DKDFigure 1 Changes in glomerular IGFBP expression observed in type 2 DKD
Figure 1 Changes in glomerular IGFBP expression observed in type 2 DKD
Figure 2 The expression of IGFBP-1 in human glomeruli and podocytes is regulated by FoxO1
Figure 2 The expression of IGFBP-1 in human glomeruli and podocytes is regulated by FoxO1
This study confirmed the new role of IGFBP-1 in the regulation of podocyte function, and in the early stage of type 2 DKD, by reducing the activity of FoxO1, the glomerular expression of IGFBP-1 was reduced
Lay AC, Hale LJ, Stowell-Connolly H,et al, IGFBP-1 expression is reduced in human type 2 diabetic glomeruli and modulates β1-integrin/FAK signalling in human podocytes.
IGFBP-1 expression is reduced in human type 2 diabetic glomeruli and modulates β1-integrin/FAK signalling in human podocytes.
Leave a message here